

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LIPPO LIMITED

力寶有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 226)

LIPPO CHINA RESOURCES LIMITED

力寶華潤有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 156)

JOINT ANNOUNCEMENT

INSIDE INFORMATION

**UPDATE ON THE CONDITIONAL EXIT OFFER FOR THE PROPOSED
VOLUNTARY DELISTING OF HEALTHWAY MEDICAL CORPORATION LIMITED**

Reference is made to the joint announcement issued by Lippo and LCR dated 3 July 2023 (the “**Announcement**”). Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meaning as defined in the Announcement.

This joint announcement is made pursuant to rule 13.09 of the Listing Rules and the Inside Information Provisions (as defined in the Listing Rules).

The respective Boards of Lippo and LCR wish to update their respective shareholders and potential investors on the further developments in relation to the Delisting and Exit Offer.

On 28 September 2023, Healthway convened and held the Healthway EGM to seek the approval of the shareholders of Healthway for the Delisting pursuant to Rules 1307 and 1308 of the Catalist Rules and certain proposed amendments to the Healthway Constitution. The resolutions to approve the Delisting and to amend the Healthway Constitution were duly passed by the shareholders of Healthway by way of poll.

As disclosed in the Announcement, the LCR Group would not participate in the Delisting Proposal and the Exit Offer and has abstained from voting at the Healthway EGM on the resolutions to approve the Delisting and to amend the Healthway Constitution.

As the resolutions that were put to vote at the Healthway EGM have been passed and the minimum acceptance condition for the Exit Offer has been satisfied, the Exit Offer has become unconditional in all respects as at 28 September 2023. The Delisting will be conditional upon approval from the SGX-ST.

For more details of the resolutions passed at the Healthway EGM and the latest update on the Delisting and the Exit Offer, please refer to the announcement made by Healthway posted on the website of each of the SGX-ST (at www.sgx.com) and Healthway dated 28 September 2023.

Shareholders and potential investors of each of Lippo and LCR are advised to exercise caution when dealing in the shares of each of Lippo and LCR.

By Order of the Board
LIPPO LIMITED
John Luen Wai Lee
*Managing Director and
Chief Executive Officer*

By Order of the Board
LIPPO CHINA RESOURCES LIMITED
John Luen Wai Lee
Chief Executive Officer

Hong Kong, 29 September 2023

As at the date of this announcement, the board composition of each of Lippo and LCR is as follows:

Lippo

Executive Directors:

Dr. Stephen Riady (*Chairman*)
Mr. John Luen Wai Lee
(*Managing Director and
Chief Executive Officer*)
Mr. Brian Riady

Non-executive Directors:

Mr. Jark Pui Lee
Mr. Leon Nim Leung Chan

Independent Non-executive Directors:

Mr. King Fai Tsui
Mr. Victor Ha Kuk Yung
Ms. Min Yen Goh

LCR

Executive Directors:

Dr. Stephen Riady (*Chairman*)
Mr. John Luen Wai Lee
(*Chief Executive Officer*)
Mr. James Siu Lung Lee
Mr. Brian Riady

Non-executive Director:

Mr. Leon Nim Leung Chan

Independent Non-executive Directors:

Mr. Edwin Neo
Mr. Victor Ha Kuk Yung
Ms. Min Yen Goh